宇信科技 reported revenue of ¥1.29B for the period ended 2026-06-30, -8.7% year on year. Net income was ¥0.31B, a 23.7% net margin on a 33.4% gross margin. The largest revenue line is 银行IT解决方案 at 87% of the total. Free cash flow for the period was ¥-0.39B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.29B | -8.7% |
| Gross profit | ¥0.43B | — |
| Operating income | ¥0.33B | — |
| Net income | ¥0.31B | +39.0% |
| Gross margin | 33.4% | Net margin 23.7% |
| Revenue Q/Q | +57.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 银行IT解决方案 | ¥1.13B | 87.2% |
| 非银IT解决方案 | ¥0.11B | 8.3% |
| 创新运营业务 | ¥0.06B | 4.4% |
| 其他(补充) | ¥0.00B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.86B | 66.6% |
| R&D | ¥0.13B | 10.3% |
| SG&A | ¥0.17B | 13.0% |
| Tax & other | ¥0.02B | 1.8% |
| Item | Amount |
|---|---|
| Total assets | ¥5.91B |
| Total liabilities | ¥1.20B |
| Shareholders' equity | ¥4.71B |
| Equity / assets | 79.7% |
| Operating cash flow | ¥-0.39B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.39B |
| Cash conversion (OCF / net income) | -216% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
建科院 ・ 华大基因 ・ 英科医疗 ・ 中科信息 ・ 电连技术 ・ 隆盛科技 ・ 英搏尔 ・ 朗新科技 ・ 海特生物 ・ 中石科技 ・ 艾德生物 ・ 智动力
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies